JPH04500688A - 肥満および本態性高血圧および関連疾患の治療 - Google Patents

肥満および本態性高血圧および関連疾患の治療

Info

Publication number
JPH04500688A
JPH04500688A JP2509673A JP50967390A JPH04500688A JP H04500688 A JPH04500688 A JP H04500688A JP 2509673 A JP2509673 A JP 2509673A JP 50967390 A JP50967390 A JP 50967390A JP H04500688 A JPH04500688 A JP H04500688A
Authority
JP
Japan
Prior art keywords
amylin
insulin
glucose
obesity
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2509673A
Other languages
English (en)
Japanese (ja)
Inventor
クーパー、ガース・ジェー・エス
レイソン、ブレンダン
Original Assignee
アミリン・コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アミリン・コーポレイション filed Critical アミリン・コーポレイション
Publication of JPH04500688A publication Critical patent/JPH04500688A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
JP2509673A 1989-07-10 1990-07-10 肥満および本態性高血圧および関連疾患の治療 Pending JPH04500688A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37765289A 1989-07-10 1989-07-10
US377,652 1989-07-10

Publications (1)

Publication Number Publication Date
JPH04500688A true JPH04500688A (ja) 1992-02-06

Family

ID=23490003

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2509673A Pending JPH04500688A (ja) 1989-07-10 1990-07-10 肥満および本態性高血圧および関連疾患の治療

Country Status (14)

Country Link
EP (1) EP0408294B1 (de)
JP (1) JPH04500688A (de)
AT (1) ATE128032T1 (de)
AU (1) AU620727B2 (de)
CA (1) CA2020786A1 (de)
DE (1) DE69022501T2 (de)
DK (1) DK0408294T3 (de)
ES (1) ES2080802T3 (de)
FI (1) FI911179A0 (de)
GR (1) GR3018442T3 (de)
IE (1) IE71195B1 (de)
NO (1) NO910901L (de)
NZ (1) NZ234428A (de)
WO (1) WO1991000737A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528198A (ja) * 2013-07-03 2016-09-15 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 抗ｃｇｒｐ抗体を使用したグルコース代謝の調整

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
EP0503827A1 (de) * 1991-03-15 1992-09-16 Pfizer Inc. Verwendung von Amylin und Calcitonin-Genverwandten Peptiden und Antagonisten davon
WO1992020367A1 (en) * 1991-05-24 1992-11-26 Amylin Pharmaceuticals, Inc. Treatment of anorexia and related states
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
DK0567626T3 (da) * 1991-11-19 2001-12-17 Amylin Pharmaceuticals Inc Amylin-agonist-peptider og anvendelse deraf
WO1993019774A1 (en) * 1992-04-03 1993-10-14 Amylin Pharmaceuticals, Inc. Amylin and possibly insulin containing composition for the treatment of anorexia and related states
DE69333683T2 (de) * 1992-05-15 2005-10-27 Amylin Pharmaceuticals, Inc., San Diego Antikörper-testbesteck zur bestimmung von amylin
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
US5625032A (en) * 1993-07-21 1997-04-29 Amylin Pharmaceuticals, Inc. Selective amylin antagonist peptides and uses therefor
WO1996003993A2 (en) * 1994-08-05 1996-02-15 The Rockefeller University Modulation of thymocyte and t cell functional activity
US6187991B1 (en) * 1995-05-23 2001-02-13 Pfizer Inc Transgenic animal models for type II diabetes mellitus
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
CN1296384C (zh) * 1999-06-18 2007-01-24 普罗特米克斯发现有限公司 具有preptin功能的肽
DK1957106T4 (da) 2005-11-14 2019-10-28 Teva Pharmaceuticals Int Gmbh Antagonist-antistoffer, der er rettet mod calcitonin-gen-relateret peptid og fremgangsmåder til anvendelse af disse
ES2689322T3 (es) 2008-03-04 2018-11-13 Teva Pharmaceuticals International Gmbh Métodos para tratar el dolor crónico
US8623366B2 (en) 2009-08-28 2014-01-07 Labrys Biologics, Inc. Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
CN102666579A (zh) * 2009-10-30 2012-09-12 诺沃—诺迪斯克有限公司 降钙素基因相关肽的衍生物
KR20220130822A (ko) 2014-03-21 2022-09-27 테바 파마슈티컬스 인터내셔널 게엠베하 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
EP3515937A1 (de) 2016-09-23 2019-07-31 Teva Pharmaceuticals International GmbH Behandlung von refraktärer migräne

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052583T3 (es) * 1986-12-04 1994-07-16 Asahi Chemical Ind Derivados de peptidos relacionados con el gel calcitonina.
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
WO1989006135A1 (en) * 1988-01-11 1989-07-13 Amylin Corporation Treatment of type 2 diabetes mellitus

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016528198A (ja) * 2013-07-03 2016-09-15 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 抗ｃｇｒｐ抗体を使用したグルコース代謝の調整

Also Published As

Publication number Publication date
ES2080802T3 (es) 1996-02-16
WO1991000737A1 (en) 1991-01-24
DK0408294T3 (da) 1996-01-15
NO910901L (no) 1991-04-25
EP0408294A2 (de) 1991-01-16
DE69022501D1 (de) 1995-10-26
EP0408294B1 (de) 1995-09-20
AU620727B2 (en) 1992-02-20
NO910901D0 (no) 1991-03-07
IE902514A1 (en) 1991-02-13
AU5953790A (en) 1991-02-06
FI911179A0 (fi) 1991-03-08
DE69022501T2 (de) 1996-02-01
GR3018442T3 (en) 1996-03-31
CA2020786A1 (en) 1991-01-11
ATE128032T1 (de) 1995-10-15
EP0408294A3 (en) 1991-12-18
NZ234428A (en) 1997-08-22
IE71195B1 (en) 1997-02-12

Similar Documents

Publication Publication Date Title
JPH04500688A (ja) 肥満および本態性高血圧および関連疾患の治療
US5364841A (en) Treatment of obesity and essential hypertension and related disorders
US20210213106A1 (en) Treatment of short bowel syndrome patients with colon-in-continuity
JP3821839B2 (ja) 胃腸の運動性を調節する方法
Calvo et al. The rat placenta and the transfer of thyroid hormones from the mother to the fetus. Effects of maternal thyroid status
Frystyk et al. Increased levels of circulating free insulin-like growth factors in patients with non-islet cell tumour hypoglycaemia
BRPI0007820B1 (pt) formulações farmacêuticas agonistas de exendina e seus usos
US8071368B2 (en) Methods for promoting growth and survival of insulin-secreting cells
US5280014A (en) Treatment of obesity and essential hypertension and related disorders
Landau et al. A novel somatostatin analogue prevents early renal complications in the nonobese diabetic mouse
Tessari Changes in protein, carbohydrate, and fat metabolism with aging: possible role of insulin
Park et al. Endocrine disorders associated with obesity
Kannan The pituitary gland
Liddle Integrated actions of cholecystokinin on the gastrointestinal tract: use of the cholecystokinin bioassay
US20040022807A1 (en) Methods for treating obesity
Elitsur et al. The proximal convoluted tubule is a target for the uroguanylin‐regulated natriuretic response
WO2024125274A1 (zh) Feimin在调节糖稳态中的用途
Coenraad et al. Physiologic hyperleptinemia in obesity does not affect vasopressin secretion in acute hypo-or hyperosmolality
Troke A Medical Bypass
Underwood et al. Potential Therapeutic Uses of Insulin-like Growth Factor I
Sirek et al. Growth hormone problems featured at Mont Gabriel workshop on diabetes
US20040096433A1 (en) Regulation of angiontensin II receptors in mammals subject to fetal programming
Verchere Control of insulin secretion from the perfused rat pancreas: effects of acetylcholine and a somatostatin analog, SMS 201-995
Nestler 19 Insulin Resistance Effects
Ng MA Heffernan1, AW Thorburn2, B Fam2, R Summers3, B Conway-Campbell4, MJ Waters4 and